HomeLatestAMC Pivots to Precious Metals to Stop the Bleeding
AMC Pivots to Precious Metals to Stop the Bleeding
March 15, 2022 at 12:51 pm - by Kevin Flynn
AMC Pivots to Precious Metals to Stop the Bleeding
AMC Entertainment (AMC), the darling of the meme stock world just a few short months ago, has been slowly bleeding out since September. Their Reddit-induced high of $62.55 in 2021 is down to a measly $14.13 this morning. This week, in a desperate attempt to breathe life back into the company, they bought 22% of Hycroft Mining (HYMC). AMC is digging for gold.
Hycroft is a Nevada-based gold and silver mining company that’s been trading barely above penny stock levels in 2022. Their year-end closing price was 61¢ a share. On March 10th, they were at 67¢. Watch it this week. The Reddit Raiders have gotten ahold of the story. At 9:30 am on Tuesday, after Seeking Alpha profiled the deal, Hycroft went from $1.39 to $2.70.
Gold Mining Won’t Save AMC Entertainment
A bad bet is a bad bet. AMC was overvalued last year, and this deal won’t make them a better company. Their ROI, operating margin, and profit margin are all in the red. Their target price is just $10.45, so they’re still trading above what they are worth. Any upward movement from this latest deal is nothing more than misplaced optimism in the American film industry.
Don’t get me wrong. Hycroft looks like a solid investment. The Hycroft Mine in Northern Nevada has a reported 15 million ounces of gold resources and 600 million ounces of silver. That’s 20,000 tons of US-mined precious metals. Their nearest competitor, Barrick Gold (GOLD), which owns Nevada Gold Mines, mined 4.8 million ounces of gold last year.
Are you seeing what I’m seeing? Here’s a breadcrumb for the social media crowd: Eric Sprott, one of the world’s largest investors in precious metals, also bought 22% of Hycroft this week. He and AMC each invested $27.9 million in cash to the mining company. That sounds like a war chest to me. There’s more to this deal than we’re hearing right now.
Hedging with Gold and Betting on the Meme Stock Effect
When asked to comment on the Hycroft deal, Adam Aron, chairman and CEO of AMC Entertainment said, “Our strategic investment being announced today is the result of our having identified a company in an unrelated industry that appears to be just like AMC of a year ago.” Does everyone remember what happened to AMC last year?
Aron goes on to talk about “rock-solid assets” and “liquidity issues,” but the messaging here is clear. They’re counting on the meme stock effect to drive stock prices up while they bet on the film industry to recover. Their hope is based on the success of Spiderman and Batman. Superheroes only save the day in comic books. This hole is too deep to climb out of.
Gold is a hedge. It’s not my favorite hedge, but it’s stabilized my portfolio more than once over the years. Look at this deal for what it is. Covid isn’t dead yet. Follow what’s happening in China. Movie theatres are giant petri dishes that may soon become a nostalgic memory. That saddens me, but it’s a harsh reality. Batman is not coming to save the day.
Share this article:
Disclaimer
This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…
This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.
“PCG” and its affiliates are not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does “PCG” engage in any activities that would require such registrations. “PCG” and its affiliates do not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication.
Our articles, reports/releases and videos are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We only publish favorable information because we are compensated to publish only favorable information. We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.
The contributors may buy and sell securities before, during and after any particular article, report and publication. In no event shall “PCG” or affiliates be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by “PCG”, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages.Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. Never invest in any stock featured by “PCG” and its affiliates unless you can afford to lose your entire investment.We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org.
For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures.
Following milestone news about the first potential FDA-approved treatment for the rare skin disease, Netherton Syndrome, shares of Quoin Pharmaceuticals (Nasdaq:…
Share This Article
About the Author
Kevin Flynn
A former financial professional and founder of AdvisorScale Financial Writing, Kevin lives in Leominster, Massachusetts with his wife Evelyn, two cats, and nine wonderful grandchildren.
